Synonyms
N-Methylisoindigotin; Natura-α
Description
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity.
Structural Formula
Meisoindigo
Solubility
DMSO : ≥ 51 mg/mL(184.59 mM )
Source
Plants >other families
Shipping
Room temperature in continental US; may vary elsewhere.
SMILES
O=C1N(C)C2=C(C=CC=C2)/C1=C3C(NC4=C\3C=CC=C4)=O
In Vivo
Meisoindigo (Dian III; 50-150 mg/kg; IP; daily; for 14 days) has anti-leukemic activity in vivo. Meisoindigo (2, 4, 8, 12 mg/kg; IP; before MCAO and 2 h after reperfusion) significantly reduces infarct volume, ameliorates neurological deficits 3 days after middle cerebral artery occlusion (MCAO) in Wild-type C57BL/6J mice (25-30 g). Meisoindigo reduces edema and lowers AQP4 expression in the brain. Animal Model:NOD/SCID mice, 6-8 weeks old, with HL-60 leukemic cellsDosage:50, 100, 150 mg/kgAdministration:IP; daily; for 14 daysResult:Had anti-leukemic activity in vivo.
In Vitro
Meisoindigo (Dian III; 5-20 μM; for 24 hours) inhibits growth of the AML cell lines. Meisoindigo (10 μM; for 24 hours) induces apoptosis of acute myeloid leukemia. Meisoindigo (5-10 μM; for 24 hours) causes cell-cycle arrest. Meisoindigo (5-10 μM; for 24 hours) increases the cleaved caspase-3 and pro-apoptotic Bak, and decreases Bcl-2 and Bcl-xL levels in HL-60 cells. Meisoindigo (10, 30, 50, 100, 150 μM; 24 hours) interdicts LPS-induced (1 μg/mL) NLRP3 inflammasome activation and M1/M2 polarization through down-regulation of TLR4 pathways after OGD/R in HT-22 and BV2 cells.
Datasheet 
